Stock vs Stock Comparison

Boston Scientific Corporation vs AbbVie Inc.

BSX wins the Tale of the Tape 5–3.

BSX$44.03
ABBV$254.49

🏆 Tale of the Tape

53
BSXABBV
14.4%Profitability (Net Margin)6.9%
18.7xValuation (P/E)124.8x
7.7%Efficiency (ROIC)8.3%
7/9Health (Piotroski F)7/9
3.1Safety (Altman Z)2.4
19.9%Growth (Rev YoY)8.6%
-2.36Risk (Sharpe 1Y)1.11
0.78xBalance Sheet (D/E)-42.50x
4.57%FCF Yield3.54%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.155
252-Day Correlation
0.178
126-Day Correlation

Low correlation — excellent diversification pair.

Fundamentals

MetricBSXABBV
Market Cap$65.4B$449.6B
P/E Ratio18.7x124.8x
Forward P/E11.9x15.6x
P/B2.53x-67.56x
Dividend Yield2.72%
Beta0.580.28

Quantitative Metrics

MetricBSXABBV
DCF Fair Value$97.76$123.27
DCF Upside+122.0%-51.6%
Piotroski F7/97/9
Altman Z3.062.37
Beneish M-2.52-2.87
FCF Yield4.57%3.54%
Net Debt/EBITDA1.8x3.0x
ROIC7.7%8.3%
WACC7.8%7.5%
ROIC – WACC-0.1pp0.7pp
Gross Margin69.0%70.2%
Net Margin14.4%6.9%
Rev Growth YoY19.9%8.6%
Sharpe (1Y)-2.361.11
Max Drawdown 3Y
FCF Payout Ratio65%

BSX Price

Loading chart...

ABBV Price

Loading chart...

ETF Exposure

BSX found in:

XHE1.42%
XLV1.13%
VHT0.93%
SCHV0.38%
MGK0.28%
IVV0.25%
SPLG0.25%
IWD0.25%
ITOT0.22%
ESGV0.19%
SCHX0.18%
VONV0.18%
SCHB0.17%
VFMV0.16%
RSP0.16%
MGV0.15%
URTH0.13%
SPYG0.13%
VTV0.12%
QUS0.11%
SPY0.10%
VOO0.10%
VUG0.10%
SPTM0.10%
VTI0.09%
VONE0.09%
ACWI0.09%
SPYV0.07%
IWF0.06%
VT0.05%
ONEO0.03%

ABBV found in:

XLV7.69%
IYH7.48%
VHT6.56%
HDV5.44%
SCHD3.53%
DGRO3.05%
MGV2.10%
VIG1.94%
DGRW1.93%
VYM1.85%
JEPI1.73%
VTV1.66%
SDY1.61%
NOBL1.49%
IWF1.39%
SCHV1.38%
VONV1.15%
XBI1.11%
SPYV0.82%
ESGV0.78%
IVV0.72%
SPY0.69%
VOO0.69%
SPLG0.68%
SCHX0.66%
SPTM0.64%
VONE0.64%
ITOT0.63%
SCHB0.62%
VTI0.61%
SPYG0.59%
URTH0.48%
VFVA0.41%
VT0.38%
QUS0.38%
ACWI0.38%
VFMV0.25%
RSP0.18%
VONG0.11%
ONEO0.03%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

BSX vs ABBV: Head-to-Head Analysis

Boston Scientific Corporation (BSX) and AbbVie Inc. (ABBV) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, BSX leads 5–3 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, BSX generates a return on invested capital (ROIC) of 7.7% compared to ABBV's 8.3%. This suggests ABBV is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between BSX and ABBV is 0.155, indicating low correlation, making them an effective diversification pair in a portfolio context.

BSX appears in 31 ETFs tracked by SecuritiesDB, while ABBV appears in 40 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, BSX or ABBV?

Our quantitative analysis compares BSX and ABBV across nine fundamental dimensions. BSX wins the Tale of the Tape 5–3. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are BSX and ABBV correlated?

The 252-day correlation between BSX and ABBV is 0.155. They have low correlation, offering good diversification.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.